- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ACCC 2019: On Location Interviews, Day 1
On day 1 of the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, we spoke with Tom Gallo, the outgoing president of ACCC and Nicole Braccio, PharmD, director of policy at the National Patient Advocate Foundation.
Today-
We are on site in Washington, DC, at the Association of Community Cancer Centers’ Annual Meeting and Cancer Center Business Summit!
We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Tom Gallo, the outgoing president of ACCC on trends in oncology care and preparing for the future, and Nicole Braccio, PharmD, of the National Patient Advocate Foundation on shared decision making and other conversations with patients.
Welcome to AJMC® On Location! I’m Jaime Rosenberg.
The meeting kicked off with a look into the future, with sessions that analyzed how physicians, nurses and administrators will adapt over the next 10 years as cancer practices grapple with business, quality, and technology trends. There was also a session on federal policy shifts that impact care delivery, reimbursement, and patient access to care, as well as the government’s role in changing the healthcare landscape.
Read about these stories and watch additional interviews from the meeting at AJMC.com.
That’s all for today. Stay tuned for tomorrow’s AJMC® On Location, where we will sit down with James Hamrick, MD, of Flatiron Health to discuss technology in care delivery, and Ali McBride, PharmD, to discuss biosimilars and more.
Thank you for watching AJMC® News Network! I’m Jaime Rosenberg.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
